SCORE2: Visual acuity results with bevacizumab non-inferior to aflibercept as treatment for macular edema due to CRVO

The SCORE2 study showed that intravitreal bevacizumab is non-inferior to aflibercept as a treatment for macular edema due to central retinal or hemiretinal vein occlusion with respect to visual acuity. The trial involved 66 centers in the U.S. and included 362 patients randomized to receive 1.25 mg Avastin (bevacizumab, Genentech) or 2 mg Eylea (aflibercept, Regeneron) every 4 weeks over a period of 6 months. Bevacizumab was divided into single dose units by the Investigational Drug Service of the University of Pennsylvania. The primary outcome was mean change in best-corrected ETDRS visual acuity letter score and the non-inferiority margin was five letters. Visual acuity assessment, OCT examination, fundus photography and flourescein angiography were performed at each monthly visit.